Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Talabostat - BioXcel Therapeutics

Drug Profile

Talabostat - BioXcel Therapeutics

Alternative Names: BXCL 701; PT-100; Talabostat mesilate; Talabostat mesylate; ValboroPro

Latest Information Update: 22 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tufts University School of Medicine
  • Developer BioXcel Therapeutics; Midatech Pharma US
  • Class Antineoplastics; Boronic acids; Dipeptides; Pyrrolidines; Small molecules
  • Mechanism of Action Dipeptidyl peptidase 8 inhibitors; Dipeptidyl peptidase 9 inhibitors; Fibroblast activation protein antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma; Pancreatic cancer; Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Pancreatic cancer; Prostate cancer
  • Preclinical Acute myeloid leukaemia
  • Discontinued Chronic lymphocytic leukaemia; Malignant melanoma; Neutropenia; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 18 Oct 2019 Phase I/II trials in Pancreatic cancer (Combination therapy) in USA (PO) before October 2019 (Bioxcel therapeutics pipeline October 2019)
  • 18 Oct 2019 The U.K. Medicines and Healthcare products Regulatory Agency (MHRA) accepts the Clinical Trial Application (CTA) for talabostat in combination with pembrolizumab for Prostate cancer before October 2019(Biocxel therapeutics pipeline October 2019)
  • 18 Oct 2019 The USFDA approves the IND application for talabostat in combination with bempegaldesleukin and avelumab for pancreatic cancer before October 2019 (Bioxcel therapeutics pipeline October 2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top